PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
86138114 |
LAW OFFICE ASSIGNED |
LAW OFFICE 108 |
MARK SECTION |
MARK |
PONTRA |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
PONTRA |
OWNER SECTION |
NAME |
Eli Lilly and Company |
STREET |
Lilly Corporate Center |
CITY |
Indianapolis |
STATE |
Indiana |
ZIP/POSTAL CODE |
46285 |
COUNTRY |
United States |
PHONE |
317 276 9624 |
FAX |
317 276 1919 |
EMAIL |
XXXX |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders,
atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders,
cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal
diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases
and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep
disorders, urological disorders; antidepressants; Diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of
neurodegenerative amyloid diseases |
GOODS OR SERVICES DELETED FROM THE APPLICATION |
preparations |
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders,
atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders,
cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal
diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases
and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep
disorders, urological disorders; antidepressants; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative
amyloid diseases |
EXTENSION SECTION |
EXTENSION NUMBER |
1 |
ALLOWANCE MAIL DATE |
06/17/2014 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT |
150 |
TOTAL AMOUNT |
150 |
SIGNATURE SECTION |
SIGNATURE |
/blongbottom/ |
SIGNATORY'S NAME |
Bruce W. Longbottom |
SIGNATORY'S POSITION |
Assistant General Counsel |
DATE SIGNED |
11/07/2014 |
SIGNATORY'S PHONE NUMBER |
317 651 1346 |
FILING INFORMATION |
SUBMIT DATE |
Fri Nov 07 10:54:07 EST 2014 |
TEAS STAMP |
USPTO/ESU-XX.X.XX.XX-2014
1107105407089091-86138114
-500d7b6677510d54d49446ba
2a1eda348bfa97d9da5bd9237
2eafbe5fef9ec-DA-8659-201
41106184638215751 |
PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: PONTRA
SERIAL NUMBER: 86138114
The applicant, Eli Lilly and Company, having an address of
Lilly Corporate Center
Indianapolis, Indiana 46285
United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 06/17/2014.
For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune
diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic
fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders,
inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders,
neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders,
urological disorders; antidepressants; Diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative
amyloid diseases
This filing does
NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods/services are
permanently deleted from this application: preparations
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and
disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia,
dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and
inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative
diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders;
antidepressants; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases
This is the first extension request.
A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
Declaration
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false
statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and
that all statements made on information and belief are believed to be true.
Signature: /blongbottom/ Date Signed: 11/07/2014
Signatory's Name: Bruce W. Longbottom
Signatory's Position: Assistant General Counsel
Signatory's Phone: 317 651 1346
RAM Sale Number: 86138114
RAM Accounting Date: 11/07/2014
Serial Number: 86138114
Internet Transmission Date: Fri Nov 07 10:54:07 EST 2014
TEAS Stamp: USPTO/ESU-XX.X.XX.XX-2014110710540708909
1-86138114-500d7b6677510d54d49446ba2a1ed
a348bfa97d9da5bd92372eafbe5fef9ec-DA-865
9-20141106184638215751